Vote against Proposition 38, which proposes an .4 billion funding measure considered unnecessary and unhelpful.

As Californians prepare to vote on Proposition 38 in the upcoming November election, a considerable debate has emerged regarding the measure’s implications for the state’s funding of immunology and immunotherapy research. The proponents of Proposition 38 advocate for the approval of .4 billion in bonds that they claim will significantly accelerate research aimed at saving lives. However, experts and critics are raising concerns over the merit and transparency of the proposed funding plan.

According to the details outlined in the measure, half of the funds generated from the bond issuance would be allocated as competitive research grants. The remaining half, however, must be directed to a singular nonprofit medical research institute that meets stringent criteria. These conditions include establishing an affiliation with a University of California campus and possessing a significant physical infrastructure, including a minimum size of 200,000 square feet and robust healthcare system metrics, such as over 35,000 inpatient admissions and 3.5 million outpatient visits annually.

Intriguingly, a CalMatters investigation reveals that these specifications effectively limit eligibility to one organization: the California Institute for Immunology and Immunotherapy. This institute is notably backed by billionaire Gary K. Michelson, who is also a primary supporter of the Proposition 38 initiative.

Critics of the proposition, including Dr. Robert Kaplan, a former professor at UCLA, argue that such a financing strategy via a ballot initiative is misguided. He, along with David Panush, president of California Health Policy Strategies, co-chairs the campaign opposing Proposition 38. They contend that resorting to a massive bond measure is not the proper avenue for funding vital medical research. They emphasize the need to advocate for reinstating federal support rather than placing the financial burden on California taxpayers.

While supporters of Proposition 38 claim that the bonds will “pay for themselves” through a requirement for pharmaceutical companies benefiting from the research to contribute 10% of their profits back to the state, critics express skepticism regarding this assertion. Kaplan points out that similar pledges made in conjunction with California’s previous stem cell research funding initiative fell significantly short of expectations, with returns amounting to less than 1% of the associated costs.

Moreover, financial analysts from the Legislative Analyst’s Office highlight the overarching fiscal implications of the bond, projecting repayment costs could reach between 0 million to 0 million, which would be drawn from California’s general fund over two decades. This sum could potentially be leveraged to address pressing issues such as homelessness and public safety or to mitigate the need for future tax increases.

Ultimately, the debate surrounding Proposition 38 remains pivotal, as it underscores significant questions regarding fiscal responsibility, transparency, and the management of public resources in advancing critical scientific research. As California voters prepare to weigh this measure, it becomes crucial to consider the broader implications of such a substantial financial commitment.

Media News Source suggests that a more transparent and accountable approach to funding research through channels that undergo public scrutiny would be more beneficial than Proposition 38 as it currently stands.